Dicarboxylic acid derivatives with pharmaceutical properties

A method for treating angina pectoris, ischemia or cardiac insufficiency in a host, comprising administering to a host in need thereof, an effective amount of at least one compound capable of stimulating soluble guanylate cyclase independently of the heme group in the enzyme, represented by the formula:

• wherein
• B represents aryl having from 6 to 10 carbon atoms or an aromatic heterocycle having 1 to 9 carbon atoms and up to 3 heteroatoms from the group consisting of S, N and O;
• W is CH2CH2, CH═CH, CH2O, OCH2, CH2NH—, NHCH2, or CH2NHCH2;
• X is CH2)4, CH2CH2SCH2 or CH2CH2N(R′)CH2, in which R′ is H, methyl, or benzyl;
• U is CH2, O, NH, S, S(O), or S(O)2;
• A is phenyl;
• R1 is —COOR35, in which R35 represents hydrogen or straight-chain or branched alkyl having up to 6 carbon atoms;
• R2 is —COOR26, in which R26 represents hydrogen or straight-chain or branched alkyl having up to 4 carbon atoms;
• R3 is hydrogen, F, Cl, Br, straight-chain or branched alkyl, straight-chain or branched halogenoalkyl, straight-chain or branched alkoxy or straight-chain or branched halogenoalkoxy having in each case up to 4 carbon atoms;
• r is 1;
• V is absent or represents O, NH or S;
• Q is absent or represents straight-chain or branched alkylene, straight-chain or branched alkenediyl having in each case up to 15 carbon atoms, which may contain one or more groups selected from O, S(O)p, NR5, CONR5, S—CO— and OCO and which may be mono- or disubstituted by halogen or hydroxyl, or represents CONR5,
• in which
• R5 represents hydrogen,
• p represents 0 or 1,
• Y represents hydrogen, NR6R7, phenyl, napthyl or a heterocycle selected from the group consisting of
• where the cyclic radicals may in each case be mono- to trisubstituted by straight-chain or branched alkyl, straight-chain or branched alkenyl, straight-chain or branched alkinyl, straight-chain or branched alkoxy, straight-chain or branched halogenoalkyl, straight-chain or branched halogenoalkoxy having in each case up to 4 carbon atoms, straight-chain or branched cycloalkyl having 3 to 7 carbon atoms, F, CI, Br, I, NO2, COR8, SR8, NR10R11 NR9COR12 or CONR13R14,
• in which
• R6 and R7 in each case independently of one another represent hydrogen, straight-chain or branched alkyl, straight-chain or branched alkoxy or straight-chain or branched alkyloxyalkyl having in each case up to 4 carbon atoms or cycloalkyl having 3 to 8 carbon atoms or aryl having 6 to 10 carbon atoms, which is optionally mono- or polysubstituted by aryl having 6 to 10 carbon atoms or an aromatic heterocycle having 1 to 9 carbon atoms and up to 3 heteroatoms from the group consisting of S, N and O,
• R8 represents hydrogen, straight-chain or branched alkyl having up to 4 carbon atoms, or straight-chain or branched halogenoalkyl having up to 4 carbon atoms,
• R9 hydrogen, or straight-chain or branched alkyl having up to 4 carbon atoms,
• R10, R11, R13 and R14 independently of one another represent hydrogen, straight-chain or branched alkyl having up to 4 carbon atoms, or phenyl, where the phenyl radical may be mono- to trisubstituted by F, Cl, Br, hydroxyl, methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, i-butyl, t-butyl, methoxy, ethoxy, amino, acetylamino, NO2, CF3, OCF3 or CN, or two substituents R10 and R11 or R13 and R14 may be attached to one another forming a five- or six-membered ring which may be interrupted by O or N,
• R12 represents hydrogen, straight-chain or branched alkyl having up to 4 carbon atoms, or phenyl,
• where the phenyl radical may be mono- to trisubstituted by F, Cl, Br, -hydroxyl, methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, i-butyl, t-butyl, methoxy, ethoxy, amino, acetylamino, NO2, CF3, OCF3 or CN;
• and/or the cyclic radicals may in each case be mono- to trisubstituted by phenyl or a heterocycle from the group consisting of
• which are attached directly or via a group selected from O, S, SO, SO2, CONR9, SO2NR9, straight-chain or branched alkylene, straight-chain or branched alkenediyl, straight-chain or branched alkyloxy, straight-chain or branched oxyalkyloxy, straight-chain or branched sulfonylalkyl, straight-chain or branched thioalkyl having in each case up to 4 carbon atoms and may be mono- to trisubstituted by straight-chain or branched alkyl, straight-chain or branched alkoxy, straight-chain or branched halogenoalkyl or straight-chain or branched alkenyl having in each case up to 4 carbon atoms, phenyl, benzyl, F, Cl, Br, I, CN, NO2, NR17R18 or NR16COR19,
• in which
• R16 represents hydrogen, straight-chain or branched alkyl having up to 8 carbon atoms or cycloalkyl having 3 to 8 carbon atoms,
• R17, R18 independently of one another represent hydrogen, straight-chain or branched alkyl having up to 8 carbon atoms, cycloalkyl having 3 to 8 carbon atoms, phenyl, where the phenyl radical may be mono- to trisubstituted by F, Cl, Br, hydroxyl, methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, i-butyl, t-butyl, methoxy, ethoxy, amino, acetylamino, NO2, CF3, OCF3 or CN or represent a radical of the formula SO2R20,
• in which
• R20 represents straight-chain or branched alkyl having up to 4 carbon atoms or phenyl,
• and
• R19 represents hydrogen, straight-chain or branched alkyl having up to 12 carbon atoms, straight-chain or branched alkenyl having up to 12 carbon atoms, aryl having 6 to 10 carbon atoms, an aromatic heterocycle having 1 to 9 carbon atoms and up to 3 heteroatoms from the group consisting of S, N and O or cycloalkyl having 3 to 8 carbon atoms, which may optionally furthermore be substituted by F, Cl Br, hydroxyl, methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, butyl, t-butyl, methoxy, ethoxy, amino, acetylamino, NO2, CF3, OCF3 or CN;
• and/or the cyclic radicals may be fused with an aromatic or saturated carbocycle having 1 to 10 carbon atoms or an aromatic or saturated heterocycle having 1 to 9 carbon atoms and up to 3 heteroatoms from the group consisting of S, N and O;
• or a salt thereof.

A method for treating arteriosclerosis, hypertension, a thromboembolic disorder, a venous disorder or a fibrotic disorder in a host, comprising administering to a host in need thereof, an effective amount of at least one compound capable of stimulating soluble guanylate cyclase independently of the heme group in the enzyme,

• represented by the formula:
• wherein
• B represents aryl having from 6 to 10 carbon atoms or an aromatic heterocycle having 1 to 9 carbon atoms and up to 3 heteroatoms from the group consisting of S, N and O;
• W is CH2CH2, CH═CH, CH2O, OCH2, CH2OCH2, CH2NH—, NHCH2, or CH2NHCH2;
• X is CH2)4, CH2CH2SCH2 or CH2CH2N(R′)CH2, in which R′ is H, methyl, or benzyl;
• U is CH2, O, NH, S, S(O), or S(O)2;
• A is phenyl;
• R1 is —COOR35, in which R35 represents hydrogen or straight-chain or branched alkyl having up to 6 carbon atoms;
• R2 is COOR26, in which R26 represents hydrogen or straight-chain or branched alkyl having up to 4 carbon atoms;
• R3 is hydrogen, F, Cl, Br, straight-chain or branched alkyl, straight-chain or branched halogenoalkyl, straight-chain or branched alkoxy or straight-chain or branched halogenoalkoxy having in each case up to 4 carbon atoms;
• r is 1;
• V is absent or represents O, NH or S;
• Q is absent or represents straight-chain or branched alkylene, straight-chain or branched alkenediyl having in each case up to 15 carbon atoms, which may contain one or more groups selected from O, S(O)p, NR5, CONR5, S—CO— and OCO and which may be mono- or disubstituted by halogen or hydroxyl, or represents CONR5,
• in which
• R5 represents hydrogen,
• p represents 0 or 1,
• Y represents hydrogen, NR6R7, phenyl, napthyl or a heterocycle selected from the group consisting of
• where the cyclic radicals may in each case be mono- to trisubstituted by straight-chain or branched alkyl, straight-chain or branched alkenyl, straight-chain or branched alkinyl, straight-chain or branched alkoxy, straight-chain or branched halogenoalkyl, straight-chain or branched halogenoalkoxy having in each case up to 4 carbon atoms, straight-chain or branched cycloalkyl having 3 to 7 carbon atoms, F, CI, Br, I, NO2, COR8, SR8, NR10R11 NR9COR12 or CONR13R14,
• in which
• R6 and R7 in each case independently of one another represent hydrogen, straight-chain or branched alkyl, straight-chain or branched alkoxy or straight-chain or branched alkyloxyalkyl having in each case up to 4 carbon atoms or cycloalkyl having 3 to 8 carbon atoms or aryl having 6 to 10 carbon atoms, which is optionally mono- or polysubstituted by aryl having 6 to 10 carbon atoms or an aromatic heterocycle having 1 to 9 carbon atoms and up to 3 heteroatoms from the group consisting of S, N and O,
• R8 represents hydrogen, straight-chain or branched alkyl having up to 4 carbon atoms, or straight-chain or branched halogenoalkyl having up to 4 carbon atoms,
• R9 hydrogen, or straight-chain or branched alkyl having up to 4 carbon atoms,
• R10, R11, R13 and R14 independently of one another represent hydrogen, straight-chain or branched alkyl having up to 4 carbon atoms, or phenyl, where the phenyl radical may be mono- to trisubstituted by F, Cl, Br, hydroxyl, methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, i-butyl, t-butyl, methoxy, ethoxy, amino, acetylamino, NO2, CF3, OCF3 or CN, or two substituents R10 and R11 or R13 and R14 may be attached to one another forming a five- or six-membered ring which may be interrupted by O or N,
• R12 represents hydrogen, straight-chain or branched alkyl having up to 4 carbon atoms, or phenyl,
• where the phenyl radical may be mono- to trisubstituted by F, Cl, Br, -hydroxyl, methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, i-butyl, t-butyl, methoxy, ethoxy, amino, acetylamino, NO2, CF3, OCF3 or CN;
• and/or the cyclic radicals may in each case be mono- to trisubstituted by phenyl or a heterocycle from the group consisting of
• which are attached directly or via a group selected from O, S, SO, SO2, CONR9 SO2NR9, straight-chain or branched alkylene, straight-chain or branched alkenediyl, straight-chain or branched alkyloxy, straight-chain or branched oxyalkyloxy, straight-chain or branched sulfonylalkyl, straight-chain or branched thioalkyl having in each case up to 4 carbon atoms and may be mono- to trisubstituted by straight-chain or branched alkyl, straight-chain or branched alkoxy, straight-chain or branched halogenoalkyl or straight-chain or branched alkenyl having in each case up to 4 carbon atoms, phenyl, benzyl, F, Cl, Br, I, CN, NO2, NR17R18 or NR16COR19,
• in which
• R16 represents hydrogen, straight-chain or branched alkyl having up to 8 carbon atoms or cycloalkyl having 3 to 8 carbon atoms,
• R17, R18 independently of one another represent hydrogen, straight-chain or branched alkyl having up to 8 carbon atoms, cycloalkyl having 3 to 8 carbon atoms, phenyl, where the phenyl radical may be mono- to trisubstituted by F, Cl, Br, hydroxyl, methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, i-butyl, t-butyl, methoxy, ethoxy, amino, acetylamino, NO2, CF3, OCF3 or CN or represent a radical of the formula SO2R20,
• in which
• R20 represents straight-chain or branched alkyl having up to 4 carbon atoms or phenyl,
• and
• R19 represents hydrogen, straight-chain or branched alkyl having up to 12 carbon atoms, straight-chain or branched alkenyl having up to 12 carbon atoms, aryl having 6 to 10 carbon atoms, an aromatic heterocycle having 1 to 9 carbon atoms and up to 3 heteroatoms from the group consisting of S, N and O or cycloalkyl having 3 to 8 carbon atoms, which may optionally furthermore be substituted by F, Cl Br, hydroxyl, methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, butyl, t-butyl, methoxy, ethoxy, amino, acetylamino, NO2, CF3, OCF3 or CN;
• and/or the cyclic radicals may be fused with an aromatic or saturated carbocycle having 1 to 10 carbon atoms or an aromatic or saturated heterocycle having 1 to 9 carbon atoms and up to 3 heteroatoms from the group consisting of S, N and O;
• or a salt thereof which is capable of stimulating soluble guanylate cyclase independently of the heme group in the enzyme.